AM281

Confirm delete?

AM281

Zoom

Cat No: 10006972

Biochemicals - Receptor Pharmacology

AM281 is a potent and selective central cannabinoid (CB1) receptor antagonist/inverse agonist (Kis = 12 nM and 4,200 nM for CB1 and CB2, respectively).{13046,21749} Structurally, it is an analog of the CB1 inverse agonist rimonabant (Item No. 9000484)...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide

Correlated keywords:

Am-281 AM 281 cannabinoids CB1 CB2 receptors antagonists AM-281 AMs 281 agonists inverse SR141716A SR-141716A SRs 141716A membranes localization cycling

Product Overview:
AM281 is a potent and selective central cannabinoid (CB1) receptor antagonist/inverse agonist (Kis = 12 nM and 4,200 nM for CB1 and CB2, respectively).{13046,21749} Structurally, it is an analog of the CB1 inverse agonist rimonabant (Item No. 9000484).{21749} It has no effect on the vanilloid TRPV1 receptor.{12165} AM281 has been used to evaluate the potential effects of compounds at CB1.{13244,21496} It has also been used to study the membrane localization and cycling of CB1.{13567}

Size	1 mg
Shipping	dry ice
CAS Number	202463-68-1
Molecular Formula	C₂₁H₁₉Cl₂IN₄O₂
SMILES	ClC1=CC(Cl)=CC=C1N2C(C3=CC=C(I)C=C3)=C(C)C(C(NN4CCOCC4)=O)=N2
Molecular Weight	557,2
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.